SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs
Novartis(US:NVS) Reuters·2026-01-12 14:43Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease, the biotec... ...